Developing EZH2-targeted therapy for lung cancer

Cancer Discovery

Volumn 6, Issue 9, 2016, Pages 949-952

  Frankel, Arthur E ^a   Liu, Xin ^b   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPI 1205; GSK 2816126; TAZEMETOSTAT; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CYTOPENIA; DIARRHEA; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012024585     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0800     Document Type: Article

References (14)

1. Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov 2016;6:1006-21.
2. Gall Troselj K, Novak Kujundzic R, Ugarkovic D. Polycomb repressive complex’s evolutionary conserved function: The role of EZH2 status and cellular background. Clin Epigenetics 2016;8:55.
3. Brooun A, Gajiwala KS, Deng YL, Liu W, Bolanos B, Bingham P, et al. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Nat Commun 2016;7: 11384.
4. Jiao L, Liu X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 2015;350:aac4383.
5. Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E, et al. S tructural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun 2016;7:11316.
6. Kipp DR, Quinn CM, Fortin PD. Enzyme-dependent lysine deprotonation in EZH2 catalysis. Biochemistry 2013;52:6866-78.
7. Brien GL, Valerio DG, Armstrong SA. Exploiting the epigenome to control cancer-promoting gene-expression programs. Cancer Cell 2016; 29: 464-76.
8. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med 2016;22: 128-34.
9. Kaniskan HU, Konze KD, Jin J. Selective inhibitors of protein methyl- transferases. J Med Chem 2015;58:1596-629.
10. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012;109:21360-5.
11. Kuntz KW, Campbell JE, Keilhack H, Pollock RM, Knutson SK, Porter-Scott M, et al. The importance of being me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat. J Med Chem 2016;59:1556-64.
12. Morera L, Lubbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics 2016;8:57.
13. Yap T. A phase 1, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor. J Clin Oncol 2016; 34: Abstr TPS2595.
14. Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V, et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 2016;35:558-66.